Changeflow GovPing Pharma & Drug Safety MSP Nanopores Protein Analysis Patent - Univers...
Routine Notice Added Final

MSP Nanopores Protein Analysis Patent - University of Washington

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3686602A1 for MSP (Mycobacterium smegmatis porin) nanopores used in protein analysis. The patent applicants are the University of Washington and The UAB Research Foundation. The invention relates to nanopore technology for analyzing proteins at the molecular level using specialized pore-forming proteins derived from Mycobacterium smegmatis.

What changed

EPO granted patent EP3686602A1 for MSP nanopore technology developed by researchers at the University of Washington and UAB Research Foundation. The patent covers the use of Mycobacterium smegmatis porin proteins as nanopores for analyzing proteins at the single-molecule level.\n\nFor biotechnology companies, academic research institutions, and diagnostic developers working with nanopore technology, this patent establishes exclusive intellectual property rights in European designated states. Organizations developing similar protein analysis methods or nanopore-based sensors should conduct freedom-to-operate analyses to assess potential licensing requirements.

What to do next

  1. Review patent claims for potential infringement in nanopore-based protein analysis research
  2. Monitor patent family for related applications in other jurisdictions
  3. Assess freedom-to-operate for any nanopore product development

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MSP NANOPORES

Publication EP3686602A1 Kind: A1 Apr 01, 2026

Applicants

University of Washington, The UAB Research Foundation

Inventors

GUNDLACH, Jens, H., NIEDERWEIS, Michael, BUTLER, Thomas, Z., PAVLENOK, Mikhail, TROLL, Mark, A., SUKUMARAN, Suja

IPC Classifications

C07K 14/35 20060101AFI20251014BHEP C12N 15/63 20060101ALI20251014BHEP

Designated States

AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3686602A1

Who this affects

Applies to
Healthcare providers Manufacturers Research institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Protein analysis technology Nanopore sequencing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Scientific Research

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.